Luis H. Camacho

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow et al. · New England Journal of Medicine · 2012 · 8K citations · Full text

Life Sciences, Immunology, Oncology +17

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.8K citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

Antoni Ribas, Luis H. Camacho, Gabriel Lopez‐Berestein et al. · Journal of Clinical Oncology · 2005 · 584 citations

Medicine, Oncology, Pharmacology +17

Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma

Luis H. Camacho, Scott Antonia, Jeffrey A. Sosman et al. · Journal of Clinical Oncology · 2009 · 314 citations

Pharmacy, Oncology, Pharmacotherapy +17

Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group

Alessandro Testori, Jon Richards, Eric D. Whitman et al. · Journal of Clinical Oncology · 2008 · 254 citations

Medicine, Oncology, Pharmacology +15